Prospective, observational, monocentric study to assess the physiological effects of dexmedetomidine and remifentanil in spontaneously breathing patients with acute hypoxemic respiratory failure receiving high-flow nasal oxygen.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years
* PaO2/FiO2 ratio ≤ 200;
* PaCO2 \< 45 mmHg;
* At least one symptom prompting the use of sedative-analgesic drugs according to the prescription of the attending physician: dyspnea and/or discomfort equal of greater than 4/10 (Visual Analog Scale - VAS), respiratory rate equal or greater than 25 breaths per minute, PaCO2\<35 mmHg, pain (Numeric Rating Scale ≥ 4 or Behavioral Pain Scale - Non-Intubated ≥ 4);
* Informed consent signature.
Exclusion Criteria:
* Pregnancy;
* Exacerbation of asthma or chronic obstructive pulmonary disease;
* Chronic lung disease, requiring oxygen therapy at home;
* Cardiogenic pulmonary oedema;
* Hemodynamic instability (systolic blood pressure \<90 mmHg or mean arterial pressure \<65 mmHg) and/or lactic acidosis (lactate \>5 mmol/L) and/or clinically diagnosed shock;
* Metabolic acidosis (pH \<7.30 with normal or hypocarbia);
* Glasgow Coma Scale \<13;
* Contraindications to esophageal balloon and/or EIT placement.
Primary outcome measure(s)
Inspiratory effort, expressed in cmH2O — During procedure Negative deflection in esophageal pressure during inspiration
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
